Inozyme Pharma
AcquiredPioneering therapies for rare diseases of abnormal mineralization.
- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- inozyme.com
- Last Round
- Series AApr 2019
- Rounds
- 2
About
Inozyme Pharma, founded in 2017 and headquartered in Boston, Massachusetts, was a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases characterized by abnormal mineralization. The company's lead program, INDEE, targeted ENPP1 deficiency, a life-threatening rare disease affecting the heart, vasculature, and skeleton. With approximately 50 employees, Inozyme went public on Nasdaq (INZY) before being acquired by BioMarin Pharmaceutical in May 2025 for $270 million.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
May 2025
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biotechnology company focused on developing and commercializing innovative, empowered monoclonal ...
Biotechnology company focused on the development of antibody-drug conjugates for the treatment of...
Specialty therapeutics company focused on gastrointestinal and hepatology diseases and programs
Clinical-stage biotech developing innovative sustained-release therapeutics for serious retinal d...
Clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases, ...
Azenta Life Sciences provides automated sample management, storage solutions, and genomics servic...